A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
1990-05-01
Target enrollment:
Participant gender:
Summary
To determine whether taking zidovudine (AZT) will change the natural course of HIV infection
in patients with AIDS-associated Kaposi's sarcoma (KS) and whether administering AZT at a
similar dose but at different intervals will reduce toxicity in a more manageable treatment
plan.
Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent.
AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will
show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether
AZT therapy will delay the development of opportunistic infections and/or KS lesions.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)